Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Dis… (NCT07472049) | Clinical Trial Compass
RecruitingNot Applicable
Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging
United Kingdom100 participantsStarted 2025-07-31
Plain-language summary
The goal of this observational study is to characterise the relationships between inflammation, microcalcification and thrombus activity in atherosclerotic plaques in peripheral and systemic vascular territories in patients with symptomatic peripheral arterial disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female aged \> 18 years
* Symptomatic atherosclerotic peripheral artery disease;
* Intermittent claudication; with ankle/arm blood pressure ratio \<0.90 or artery stenosis \>50% in addition to at least one of the following;
* \>1 vascular bed affected by atherosclerosis
* Diabetes
* Heart failure
* Chronic kidney disease (eGFR \< 60 mL/min/1.73 m2)
* Rest pain or necrosis of limb or gangrene of limb
* Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery
* Leg or foot amputation for arterial vascular indications
* Ability to give written or verbal informed consent
Exclusion Criteria:
* Contraindication to colchicine or iodinated contrast
* Long term requirement for colchicine for another clinical indication
* Active diarrhoea
* Recent lower limb revascularisation for symptomatic disease (\<6 weeks)
* Renal failure (glomerular filtration rate \<30 mL/min/1.73 m2)
* Cirrhosis or severe chronic liver disease
* Women who are pregnant or breast-feeding
* Women of child-bearing potential not protected by reliable contraception or is planning conception during the study
* Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (apart from azithrom…
What they're measuring
1
Quantification of PET tracer uptake of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF in the symptomatic lower limb(s)
Timeframe: From baseline imaging until completion imaging at 1 year